Cargando…
Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
Most forms of castration-resistant prostate cancer (CRPC) are dependent on the androgen receptor (AR) for survival. While, enzalutamide provides a substantial survival benefit, it is not curative and many patients develop resistance to therapy. Although not yet fully understood, resistance can devel...
Autores principales: | Greene, John, Baird, Anne-Marie, Casey, Orla, Brady, Lauren, Blackshields, Gordon, Lim, Marvin, O’Brien, Odharnaith, Gray, Steven G., McDermott, Raymond, Finn, Stephen P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656767/ https://www.ncbi.nlm.nih.gov/pubmed/31341219 http://dx.doi.org/10.1038/s41598-019-47189-2 |
Ejemplares similares
-
hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro
por: Lim, Marvin C. J., et al.
Publicado: (2021) -
Circular RNAs: Biogenesis, Function and Role in Human Diseases
por: Greene, John, et al.
Publicado: (2017) -
Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer
por: Greene, John, et al.
Publicado: (2021) -
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study
por: McDermott, Raymond S., et al.
Publicado: (2021) -
Carcinogenesis in prostate cancer: The role of long non-coding RNAs
por: Aird, John, et al.
Publicado: (2018)